Skip to content

Assembly Biosciences ASMB Operating Lease Liabilities

Operating Lease Liabilities at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$100.11M-6.9%
ALN
Alnylam PharmaceuticalsALNY
$218.03M-5.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$0-100%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$0-100%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$86.64M-1.7%
Absci Corporation logo
Absci CorporationABSI
$2.15M-46.4%

Other financials

Income statement

See full
Revenue$8.2M-12.8%
Operating income-$11.4M-14.4%
Net income-$9.1M-3.0%
EPS (diluted)-$0.54+53.8%

Balance sheet

See full
Cash & equivalents$31.1M+32.9%
Total debt$2.5M-17.5%
Total equity$198.6M+632%
Total assets$235.5M+138%

Cash flow

See full
Operating cash flow-$22.1M+5.7%
CapEx$19.0K
Free cash flow-$22.1M+5.6%

Valuation

See full
Market cap$480.77M+262%
Enterprise value$452.14M+302%
P/S6.8×+2.6×

Profitability

See full
Operating margin-116.8%-26.1pp
Net margin-103.6%-22.7pp
FCF margin-150%-231pp

Returns & leverage

See full
Return on equity-36.9%-15.1pp
Debt / equity-0.1×
Current ratio6.6×+4.6×

Where this comes from

Reported directly by Assembly Biosciences in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Assembly Biosciences's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Assembly Biosciences's operating lease liabilities?
Assembly Biosciences (ASMB) reported operating lease liabilities of $1.9M in Q1 2026.
How has Assembly Biosciences's operating lease liabilities changed year-over-year?
Assembly Biosciences's operating lease liabilities decreased by 23.7% year-over-year, from $2.49M to $1.9M.
What is the long-term trend for Assembly Biosciences's operating lease liabilities?
Over 5 years (2020 to 2025), Assembly Biosciences's operating lease liabilities has grown at a -21.1% compound annual growth rate (CAGR), from $6.73M to $2.06M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.